These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 31500587)

  • 1. Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study.
    Ho GF; Chai CS; Alip A; Wahid MIA; Abdullah MM; Foo YC; How SH; Zaatar A; Lam KS; Leong KW; Low JS; Yusof MM; Lee EC; Toh YY; Liam CK
    BMC Cancer; 2019 Sep; 19(1):896. PubMed ID: 31500587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam.
    Vu TH; Nguyen HTT; Dao LK; Duong CK; Nguyen CV; Doan TT; Nguyen HTT; Hoang HH; Dinh DK; Le GV; Vu TT; Truong MC; Nguyen LT
    Asian Pac J Cancer Prev; 2021 May; 22(5):1581-1590. PubMed ID: 34048189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).
    Yokoyama T; Yoshioka H; Fujimoto D; Demura Y; Hirano K; Kawai T; Kagami R; Washio Y; Ishida T; Kogo M; Tomii K; Okuno T; Akai M; Hirabayashi M; Nishimura T; Nakahara Y; Kim YH; Miyakoshi C; Yoshimura K; Hirai T;
    Lung Cancer; 2019 Sep; 135():175-180. PubMed ID: 31446992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.
    Tanaka H; Taima K; Itoga M; Ishioka Y; Baba K; Shiratori T; Sakamoto H; Tsuchiya J; Nakagawa H; Hasegawa Y; Yasugahira H; Okudera K; Takanashi S; Tasaka S
    Med Oncol; 2019 May; 36(6):57. PubMed ID: 31089973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
    Kim MH; Choi CM; Lee SY; Park CK; Chang YS; Lee KY; Kim SJ; Yang SH; Ryu JS; Lee JE; Lee SY; Park CK; Lee SH; Jang SH; Yoon SH; Jang TW
    Anticancer Res; 2022 Mar; 42(3):1615-1622. PubMed ID: 35220259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
    Paz-Ares L; Tan EH; O'Byrne K; Zhang L; Hirsh V; Boyer M; Yang JC; Mok T; Lee KH; Lu S; Shi Y; Lee DH; Laskin J; Kim DW; Laurie SA; Kölbeck K; Fan J; Dodd N; Märten A; Park K
    Ann Oncol; 2017 Feb; 28(2):270-277. PubMed ID: 28426106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experience.
    Ezeife DA; Melosky B; Tudor R; Lin S; Lau A; Panzarella T; Leighl NB
    Curr Oncol; 2018 Oct; 25(5):e385-e390. PubMed ID: 30464688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
    Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ
    Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
    Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A
    Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations.
    Imai H; Kaira K; Suzuki K; Anzai M; Tsuda T; Ishizuka T; Kuwako T; Naruse I; Nemoto K; Uchino J; Morozumi N; Ishihara S; Minato K; Hisada T
    Lung Cancer; 2018 Dec; 126():41-47. PubMed ID: 30527191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.
    de Marinis F; Laktionov KK; Poltoratskiy A; Egorova I; Hochmair M; Passaro A; Migliorino MR; Metro G; Gottfried M; Tsoi D; Ostoros G; Rizzato S; Mukhametshina GZ; Schumacher M; Novello S; Dziadziuszko R; Tang W; Clementi L; Cseh A; Kowalski D
    Lung Cancer; 2021 Feb; 152():127-134. PubMed ID: 33387727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027.
    Minegishi Y; Yamaguchi O; Sugawara S; Kuyama S; Watanabe S; Usui K; Mori M; Hataji O; Nukiwa T; Morita S; Kobayashi K; Gemma A
    BMC Cancer; 2021 Mar; 21(1):208. PubMed ID: 33648453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group.
    Sonehara K; Kobayashi T; Tateishi K; Morozumi N; Yoshiike F; Hachiya T; Ono Y; Takasuna K; Agatsuma T; Masubuchi T; Matsuo A; Tanaka H; Morikawa A; Hanaoka M; Koizumi T
    Thorac Cancer; 2019 May; 10(5):1078-1085. PubMed ID: 31006178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
    Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ
    BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
    Lu S; Shih JY; Jang TW; Liam CK; Yu Y
    Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
    Tan WL; Ng QS; Lim C; Tan EH; Toh CK; Ang MK; Kanesvaran R; Jain A; Tan DSW; Lim DW
    BMC Cancer; 2018 Dec; 18(1):1198. PubMed ID: 30509246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in Taiwan.
    Hsieh YY; Fang WT; Lo YW; Chen YH; Chien LN
    Int J Cancer; 2020 Aug; 147(4):1107-1116. PubMed ID: 31854456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib.
    Kim Y; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
    Cancer Res Treat; 2019 Apr; 51(2):502-509. PubMed ID: 29898592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for
    Pasello G; Vicario G; Zustovich F; Oniga F; Gori S; Rosetti F; Bonetti A; Favaretto A; Toso S; Redelotti R; Santo A; Bernardi D; Giovanis P; Oliani C; Calvetti L; Gatti C; Palazzolo G; Baretta Z; Bortolami A; Bonanno L; Basso M; Menis J; Corte DD; Frega S; Guarneri V; Conte P;
    Oncologist; 2019 Jun; 24(6):e318-e326. PubMed ID: 30846513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.